These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24647572)

  • 61. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
    F Martins ML; Loos NHC; Mucuk S; de Jong D; Lebre MC; Rosing H; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2021 Dec; 18(12):4371-4384. PubMed ID: 34730366
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib.
    Song YK; Park JE; Oh Y; Hyung S; Jeong YS; Kim MS; Lee W; Chung SJ
    J Pharmacol Exp Ther; 2019 Jan; 368(1):79-87. PubMed ID: 30396915
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
    Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
    Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
    Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
    Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.
    Shukla S; Zaher H; Hartz A; Bauer B; Ware JA; Ambudkar SV
    Pharm Res; 2009 Feb; 26(2):480-7. PubMed ID: 18841445
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
    Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W; Sparidans RW; Martins MLF; El-Lari M; Lebre MC; van Tellingen O; Beijnen JH; Schinkel AH
    Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
    Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
    J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 75. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
    Moreno-Sanz G; Barrera B; Armirotti A; Bertozzi SM; Scarpelli R; Bandiera T; Prieto JG; Duranti A; Tarzia G; Merino G; Piomelli D
    Pharmacol Res; 2014 Sep; 87():87-93. PubMed ID: 24993496
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
    Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
    J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.